Abstract
Small intestinal neuroendocrine tumors (SI-NETs) are the most common tumor of the small intestine. Despite typically being metastatic at the time of diagnosis, the tumors are usually indolent and associated with a relatively long survival. Nevertheless, some patients fare worse and succumb to the disease soon after diagnosis despite similar stage and grade. To date, molecular prognostic markers are lacking, and our understanding of the disease biology is incomplete. Only CDKN1B is recurrently mutated in a subset of cases. Copy number alterations, including loss of chromosome 18, are common. However, the oncogenic mediators of these alterations remain unknown. The aim of this study was to identify molecular derangements in SI-NETs and identify potential prognostic markers. Forty tumor samples (including ten paired metastatic and primary tumors) from thirty patients with unusually long or unusually short survival after diagnosis were included for whole genome sequencing. Twenty of the samples were also included for RNA Sequencing. We validate known gene mutations and copy number alterations, as well as previously described molecular subgroups. We identify potential prognostic markers based on gene expression. Finally, we identify genes whose expression is affected by the most common copy number alterations in these tumors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Lions Cancerforskningsfond, and grants by Cancerfonden to Peter Stalberg, and by grants from Region Uppsala (ALF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The regional ethical review board in Uppsala gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos